Business Wire

European Fintech Company iCard Achieves Secure Customer Verification in Under 60 Seconds with Regula’s Solutions

7.5.2025 08:00:00 CEST | Business Wire | Press Release

Share

iCard, a leading European e-money institution, has successfully upgraded its customer checks with Regula’s advanced biometric and document verification technologies. By integrating Regula Face SDK and Regula Document Reader SDK with its KYC (Know Your Customer) and risk assessment systems, iCard has moved to speedy, automated verification with improved fraud detection, and enhanced the overall experience for customers in 30+ countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506829598/en/

iCard streamlines onboarding and boosts fraud prevention by integrating Regula’s document and biometric verification technologies (Graphic: Regula)

As a licensed fintech organization, iCard must comply with strict European KYC regulations while maintaining a robust risk assessment system alongside low-effort customer experience.

Prior to implementing Regula’s solutions, manual verification processes led to inefficiencies, longer wait times, increased fraud, and potential friction for users. Customers often had to re-upload photos or wait for manual reviews, causing delays—especially outside business hours. Additionally, iCard needed a more comprehensive document verification system that was capable of recognizing a broader range of ID types.

The Regula Solution: Fast and Fraud-Free Identity Verification

To modernize and automate its verification process, iCard selected Regula’s complete solution for document and biometric verification for its industry-leading accuracy, ease of integration, and ability to meet the company’s specific requirements.

  • Regula Face SDK: Integrated into the iCard Digital Wallet app (Android and iOS), it provides fast and reliable biometric verification when a user logs in or performs a money transaction. The solution conducts instant liveness detection and face matching, preventing fraud attempts, including presentation attacks, deepfakes, or injected videos.
  • Regula Document Reader SDK: Deployed in iCard’s back-office system, it automatically authenticates ID cards, passports, and residence permits, including previously unsupported paper-based IDs. Regula’s solution reads and authenticates data from multiple document zones, including MRZs (machine-readable zones), RFID chips, and barcodes, and cross-validates the information to detect any inconsistencies that may indicate fraud.

Tangible Business Benefits

The project was completed in just one month, and the impact has been immediate:

  • Instant identity verification – Customers can now authenticate their identity in under a minute.
  • Reduced operational costs – Automated verification processes have minimized manual reviews.
  • Enhanced fraud prevention – Advanced biometric and document verification strengthen security measures.
  • Increased conversion rates – Faster verification leads to a smoother onboarding experience and reduced drop-off rates.

“Implementing Regula Face SDK and Regula Document Reader SDK has optimized our internal processes while ensuring a seamless experience for iCard Digital Wallet customers. The integration was completed in a short period, resulting in fast and secure identity verification, improved operational efficiency, and reduced fraud risks—all while boosting customer satisfaction,” says Gabriela Anastasova, Chief Product Officer at iCard.

“In today’s fintech landscape, balancing security and user convenience is critical. Customers expect seamless access, while businesses must comply with strict regulations and defend against sophisticated fraud. We are proud to support iCard in finding that perfect balance. Our solutions ensure that every identity check is robust, automated, and frictionless, allowing fintech innovators like iCard to scale securely and efficiently,” comments Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about how iCard optimized identity verification with Regula’s solutions, read the full case study on Regula’s website.

About iCard

iCard is a licensed e-money institution and a leader in the European fintech sector. With over 18 years of experience, we deliver innovative payment services to both individual and business clients. Our mission is to make financial convenience accessible to everyone. That’s why we dedicate our time and resources to creating solutions that empower people and businesses to take full control of their funds, while ensuring a seamless customer experience through secure, innovative, and hassle-free financial and technological services.

Learn more at www.icard.com.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250506829598/en/

Contacts

Kristina – ks@regulaforensics.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye